Literature DB >> 3026013

Penetration of sulbactam into the cerebrospinal fluid of patients with bacterial meningitis receiving ampicillin therapy.

J P Stahl, J P Bru, G Fredj, K W Brammer, M R Malleret, M Micoud.   

Abstract

Concentrations of sulbactam in the CSF of 18 patients with bacterial meningitis who were undergoing treatment with intravenous (iv) ampicillin were determined. Six patients received single doses of sulbactam (1 g) and 12 patients received multiple doses (four times daily) by the iv route at various intervals before lumbar punctures were performed to monitor their condition. Concentrations of sulbactam up to 12 micrograms/ml were detected in the CSF between 1 and 4 hr after dosing, the higher levels being present in the CSF of patients with the most severe meningeal inflammation. There were no significant differences in the concentrations achieved after single or multiple doses of sulbactam, and the concentrations were generally similar to the concurrent concentrations of ampicillin. It is concluded that these results as well as the antibacterial properties of sulbactam plus ampicillin support the evaluation of this combination as an alternative in the treatment of bacterial meningitis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3026013     DOI: 10.1093/clinids/8.supplement_5.s612

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  7 in total

Review 1.  Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.

Authors:  D M Campoli-Richards; R N Brogden
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

Review 3.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

4.  Use of ampicillin-sulbactam for treatment of experimental meningitis caused by a beta-lactamase-producing strain of Escherichia coli K-1.

Authors:  L Guerra-Romero; S L Kennedy; M A Fournier; J H Tureen; M G Täuber
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

Review 5.  Management of meningitis due to antibiotic-resistant Acinetobacter species.

Authors:  Baek-Nam Kim; Anton Y Peleg; Thomas P Lodise; Jeffrey Lipman; Jian Li; Roger Nation; David L Paterson
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

6.  Penetration of sulbactam and ampicillin into cerebrospinal fluid of infants and young children with meningitis.

Authors:  G Foulds; T J McBride; A K Knirsch; W J Rodriguez; W N Khan
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

7.  Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy.

Authors:  Qiang Wang; Yuanxing Wu; Biyao Chen; Jianxin Zhou
Journal:  BMC Anesthesiol       Date:  2015-03-13       Impact factor: 2.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.